Eliem Therapeutics Inc (ELYM)
10.16
+1.76
(+21.04%)
USD |
NASDAQ |
May 03, 16:00
10.14
-0.02
(-0.15%)
After-Hours: 20:00
Eliem Therapeutics Net Income (Quarterly): -3.641M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.641M |
| September 30, 2023 | -3.968M |
| June 30, 2023 | -5.22M |
| March 31, 2023 | -22.29M |
| December 31, 2022 | -7.762M |
| September 30, 2022 | -9.682M |
| June 30, 2022 | -14.60M |
| March 31, 2022 | -13.20M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.54M |
| September 30, 2021 | -9.615M |
| June 30, 2021 | -8.719M |
| March 31, 2021 | -18.60M |
| December 31, 2020 | -14.86M |
| September 30, 2020 | -2.258M |
| June 30, 2020 | -1.631M |
| March 31, 2020 | -1.916M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-22.29M
Minimum
Mar 2023
-1.631M
Maximum
Jun 2020
-9.282M
Average
-9.167M
Median
Net Income (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 5.96M |
| Candel Therapeutics Inc | -11.10M |
| Cyclacel Pharmaceuticals Inc | -5.271M |
| Lipocine Inc | -2.282M |
| GlycoMimetics Inc | -9.079M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.122M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 174.69M |
| Earnings Yield | -12.90% |